A Phase 3 interventional study of insulin degludec and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 52nd largest by enrollment, is one of 6 that started in 2012, is one of 49 in phase 3, and was the 27th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 145 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 245th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 301st registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in the United States of America (USA). The aim of the trial is to confirm the efficacy of IDeg (insulin degludec) versus IGlar (insulin glargine) in controlling glycaemia. Subjects are to continue their pre-trial metformin treatment.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 145 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec · Drug: insulin glargine
Drug: insulin degludec · Drug: insulin glargine
Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period
Values for change in HbA1c after each 16 weeks of treatment periods A and B.
Time frame: Week 0, week 16 of each treatment period.
Change in Patient Reported Outcome (PRO) Scores From Baseline to the End of Each 16 Week Treatment Period
Changes in subjects quality of life and insulin device satisfaction were evaluated using the following PROs: the Short-Form 36 Health Survey version 2 (SF-36) and the Treatment Related Impact Measure-Diabetes Device (TRIM-DD). PRO total scores were measured from baseline to the end of each 16-week treatment period. Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.
Time frame: Week 0, week 16 of each treatment period.
Change in PRO Scores From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
SF-36 and TRIM-DD total scores were measured at the end of treatment A (week 16) and 4 weeks into treatment B (week 20). Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.
Time frame: Week 16, week 20
Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period
Values of FPG in mmol/L from baseline to each 16 weeks of treatment periods.
Time frame: Week 0, week 16, week 32
Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B
Values of FPG in mmol/L from the end of treatment period A until after 4 weeks of treatment in treatment period B.
Time frame: Week 16, week 20
Number of Adverse Events (AEs)
Number of treatment emergent adverse events (TEAEs) from week 0 to week 16 of the randomised treatment periods. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. TEAEs were attributed to the treatment given in the period in which the event occurred.
Time frame: From baseline to the end of each 16 week treatment period.
The trial was conducted at 37 sites in the United States of America (USA).
| Milestone | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Started | 73 | 72 |
| Exposed | 73 | 72 |
| Completed | 70 | 67 |
| Not completed | 3 | 5 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal criteria | 0 | 1 |
| Withdrew: Unclassified | 2 | 3 |
| Milestone | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Started | 70 | 67 |
| Exposed | 70 | 67 |
| Completed | 69 | 66 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
Values for change in HbA1c after each 16 weeks of treatment periods A and B.
| percentage of glycosylated haemoglobin | IDeg | IGlar |
|---|---|---|
| Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period | -0.1 ± 1.1 | -0.1 ± 1.1 |
Changes in subjects quality of life and insulin device satisfaction were evaluated using the following PROs: the Short-Form 36 Health Survey version 2 (SF-36) and the Treatment Related Impact Measure-Diabetes Device (TRIM-DD). PRO total scores were measured from baseline to the end of each 16-week treatment period. Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.
| scores on a scale | IDeg | IGlar |
|---|---|---|
| Physical score | -0.8 ± 7.7 | -0.6 ± 7.8 |
| Mental score | 0.7 ± 9.3 | 0.4 ± 10.4 |
| Total D-device | 11.0 ± 19.1 | 3.5 ± 19.1 |
SF-36 and TRIM-DD total scores were measured at the end of treatment A (week 16) and 4 weeks into treatment B (week 20). Responses were measured on a scale of 0 to 100, where higher scores indicated a better quality of life and higher insulin device satisfaction on the SF-36 and TRIM-DD questionnaires, respectively.
| scores on a scale | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Physical score | 0.02 ± 7.07 | 0.60 ± 6.09 |
| Mental score | 0.61 ± 8.88 | 0.21 ± 8.59 |
| Total D-device | 10.24 ± 19.89 | -6.25 ± 11.10 |
Values of FPG in mmol/L from baseline to each 16 weeks of treatment periods.
| mmol/L | IDeg | IGlar |
|---|---|---|
| Change From Baseline in Central Laboratory Measured Fasting Plasma Glucose (FPG) at the End of Each 16 Week Treatment Period | -0.8 ± 4.2 | -0.0 ± 4.4 |
Values of FPG in mmol/L from the end of treatment period A until after 4 weeks of treatment in treatment period B.
| mmol/L | IDeg/IGlar | IGlar/IDeg |
|---|---|---|
| Change in FPG From the End of Treatment Period A Until After 4 Weeks of Treatment in Treatment Period B | -0.78 ± 3.41 | 0.19 ± 4.40 |
Number of treatment emergent adverse events (TEAEs) from week 0 to week 16 of the randomised treatment periods. A TEAE was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment. TEAEs were attributed to the treatment given in the period in which the event occurred.
| events | IDeg | IGlar |
|---|---|---|
| Number of Adverse Events (AEs) | 105 | 111 |
Collected over The adverse events were collected in a time frame of 32 weeks + 7 days follow up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg | — | 4/140 (2.9%) | 2/140 (1.4%) |
| IGlar | — | 4/142 (2.8%) | 9/142 (6.3%) |
| Event | IDeg | IGlar |
|---|---|---|
| Angina unstableCardiac disorders | 1/140 | 0/142 |
| MastoiditisInfections and infestations | 1/140 | 0/142 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/140 | 0/142 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 1/140 | 0/142 |
| Acute coronary syndromeCardiac disorders | 0/140 | 1/142 |
| Urinary tract infectionInfections and infestations | 0/140 | 1/142 |
| Back painMusculoskeletal and connective tissue disorders | 0/140 | 1/142 |
| EpididymitisReproductive system and breast disorders | 0/140 | 1/142 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/140 | 1/142 |
| Event | IDeg | IGlar |
|---|---|---|
| NasopharyngitisInfections and infestations | 2/140 | 9/142 |
For 4 subjects baseline fasting plasma glucose (FPG) values were missing, hence did not contribute to the FPG summary.
| Age, Continuous(years) | IDeg/IGlar | IGlar/IDeg | Total |
|---|---|---|---|
| Mean | 54.7 ± 10.2 | 55.8 ± 9.0 | 55.3 ± 9.6 |
| Sex: Female, Male(Participants) | IDeg/IGlar | IGlar/IDeg | Total |
|---|---|---|---|
| Female | 31 | 24 | 55 |
| Male | 42 | 48 | 90 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg/IGlar | IGlar/IDeg | Total |
|---|---|---|---|
| Mean | 8.0 ± 1.1 | 8.3 ± 1.4 | 8.2 ± 1.3 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg/IGlar | IGlar/IDeg | Total |
|---|---|---|---|
| Mean | 7.5 ± 3.3 | 8.5 ± 4.1 | 8.0 ± 3.7 |
The record gives a start of Apr 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 10 months after primary completion. A results delay was requested in Jan 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Glargine